KMID : 0360220180590040338
|
|
´ëÇѾȰúÇÐȸÁö 2018³â 59±Ç 4È£ p.338 ~ p.346
|
|
½ºÅ×·ÎÀÌµå »ç¿ë ÈÄ ¹ß»ýÇÑ Áß½ÉÀå¾×¸Æ¶ô¸Á¸·º´ÁõÀÇ ÀÓ»ó¾ç»ó ºñ±³
Clinical Manifestations of Steroid-associated Central Serous Chorioretinopathy
|
|
ÃÖ¼º¿ø ( Choi Sung-Won ) - °è¸í´ëÇб³ Àǰú´ëÇÐ µ¿»êÀÇ·á¿ø ¾È°úÇб³½Ç
±èÀ¯Ã¶ ( Kim Yu-Cheol ) - °è¸í´ëÇб³ Àǰú´ëÇÐ µ¿»êÀÇ·á¿ø ¾È°úÇб³½Ç
|
|
- Abstract -
|
|
|
|
Purpose: To evaluate the clinical differences between patients with central serous chorioretinopathy (CSC) developed after steroid use and CSC patients without a history of steroid use for short-term periods.
Methods: We retrospectively analyzed the medical records of 47 patients (55 eyes) diagnosed with CSC from January 2011 to August 2017 by categorizing Group 1 (32 patients, 36 eyes) without a history of steroid use and Group 2 (15 patients, 19 eyes) with a history of steroid use within 6 months. We evaluated the differences in best-corrected visual acuity (BCVA), subretinal fluid (SRF) height, subfoveal choroidal thickness (SFCT), and Haller¡¯s layer thickness in the two groups. We also analyzed the changes in the BCVA, SRF height, SFCT, and Haller¡¯s layer thickness in each group for 1 month and compared them depending on the treatment.
Results: There were no significant differences between the two groups with regard to age, sex, BCVA, bilaterality, number of leakage points, and Haller¡¯s layer thickness. Group 2 showed significantly increased SRF height and SFCT than Group 1 (p = 0.002, p = 0.005, respectively). In Group 1, the level of SRF and SFCT were significantly more decreased after 1 month (p = 0.001, 0.015, respectively) in patients with treatment than in those without treatment. In Group 2, the height of the SRF and SFCT were significantly more decreased after 1 month (p = 0.005, 0.002, respectively) in untreated patients compared to treated patients.
Conclusions: CSC patients with a prior history of steroid use have higher serous detachment and a thicker SFCT than those without prior history of steroid use. Therefore, termination of steroid treatment may reduce the SFCT and SRF in steroid-treated CSC patients.
|
|
- Key Words -
|
|
Central serous chorioretinopathy, Choroidal thickness, Steroid, Subretinal fluid
|
|
- ¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸ -
|
|
|
|
- µîÀçÀú³Î Á¤º¸ -
|
|
|
|
|
|